Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending December 08, 2004. The report details a specific corporate action regarding share repurchases authorized by shareholders at the Annual General Meeting on May 17, 2004.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share buyback transaction:
- Shares Purchased: 1,000,000 Ordinary shares of 25 pence each.
- Purchase Date: December 07, 2004.
- Purchase Price: 1,153.89 pence per share.
- Treasury Holdings: 61,748,000 shares held in Treasury following the purchase.
- Shares in Issue: 5,877,287,316 shares (excluding Treasury shares).
Material Changes
The material change reported is the reduction of outstanding shares through the acquisition of 1,000,000 shares for Treasury. The filing text does not provide comparative data against prior periods for operational or financial performance.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase or subscribe for securities.
Investor Verification Checklist
- Verify the total cost of the 1,000,000 share repurchase based on the disclosed price of 1,153.89 pence.
- Confirm the updated total share count (5,877,287,316) against subsequent filings.
- Review the Annual General Meeting minutes from May 17, 2004, to understand the full scope of the share buyback authority.
- Note that this filing does not contain quarterly or annual financial results; refer to Form 20-F for comprehensive financial data.